Jacob Steven Leach Sells 746 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $68.82 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a market capitalization of $27.37 billion, a price-to-earnings ratio of 44.40, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The business has a 50 day simple moving average of $83.24 and a 200-day simple moving average of $111.61.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the firm posted $0.34 EPS. The business’s revenue for the quarter was up 15.3% compared to the same quarter last year. As a group, equities research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the 2nd quarter worth $25,000. Sachetta LLC boosted its position in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares during the period. DSM Capital Partners LLC acquired a new position in DexCom during the 4th quarter worth $28,000. Crewe Advisors LLC acquired a new position in DexCom during the 1st quarter worth $29,000. Finally, Riverview Trust Co acquired a new position in DexCom during the 1st quarter worth $32,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on DXCM shares. UBS Group dropped their target price on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday, July 26th. JPMorgan Chase & Co. downgraded DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $145.00 to $75.00 in a report on Friday, July 26th. BTIG Research dropped their target price on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Robert W. Baird lifted their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Finally, Redburn Atlantic assumed coverage on DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.